Dr. Yuliya P.l. Linhares, MD

Dr. Linhares practices at Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida.

Dr. Linhares' NPI, 1225299563, was assigned on June 19, 2008. Dr. Linhares graduated from University of North Carolina School of Medicine in 2006. Dr. Linhares holds Florida license ME140422.

Dr. Linhares' primary practice is Baptist Health Baptist Hospital, at 8900 N Kendall Dr, Miami, FL 33176 in Miami-Dade County. The practice phone is (786) 596-1960.

Dr. Linhares' primary practice is Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida. The medical group on file is Baptist Health Medical Group Oncology. Dmand AI also links Dr. Linhares to 1 more breast imaging center, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Linhares practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Linhares' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Linhares is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Linhares' licenses on file in 2 states: Florida and California.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, lymphoma and multiple myeloma among the conditions Dr. Linhares treats.

CMS data shows 387 Medicare services from Dr. Linhares across 5 procedure codes in 2024, for 103 Medicare patients. Medicare paid $35,512 for them.

CMS counts 103 Medicare patients who saw Dr. Linhares in 2024. The largest group is 75 to 84, with 43 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 35% are also on Medicaid. Their average risk score is 2.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Linhares' median patient age at 66, with 49% women.

In 2024, Dr. Linhares wrote 152 Medicare Part D claims for 38 patients. 68% of them were for generic drugs. CMS names the drug for 73 of them, across 4 drugs with 11 or more claims each, at $308,881 in total drug cost. In 2023, CMS named 93 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Linhares for performance year 2024, reported as part of a group. Dr. Linhares accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Linhares as offering telehealth.

Dmand AI links 15 papers to Dr. Linhares, published from 2013 to 2025. 2020 was the busiest year, with 2. The most frequent topics are Hematopoietic Stem Cell Transplantation, Antigens, CD19 and Antineoplastic Combined Chemotherapy Protocols. Dr. Linhares has published most often in Support Care Cancer. Dr. Linhares' most frequent co-authors are Yazmin Odia, MD, MS, Rangaswamy Akhanda Chintapatla, MD and Michelle A. Fanale, MD.

Dmand AI links Dr. Linhares to 6 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Lymphoma, Lymphoma, B-Cell and Burkitt Lymphoma. Cedars-Sinai Medical Center sponsors the most, 2.

CMS Open Payments shows 226 general payments to Dr. Linhares from 35 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Kyowa Kirin, Inc. paid the most, $30,258. It also lists 5 research payments totaling $5,740 from 2024 to 2025.

Dr. Linhares graduated from University of North Carolina School of Medicine in 2006.

Dr. Linhares is in network with 13 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.